Skip to main content

Capital Raising and M&A in Life Sciences

Fasken combines respected securities law experience with life sciences acumen to bring unique value to our clients who want to cost-effectively raise capital and complete deals that advance their goals.
Subscribe Fasken


Life sciences deal activity and capital-raising strategies have steadily increased as the industry adapts to meet changing market and regulatory demands.

For emerging private companies, we help in the initial rounds of financing, including guidance through due diligence, refinement of governance and capital structure, preparation of subscription and offering materials, and negotiation of shareholder or other agreements to govern relationships going forward.


For later stage companies, we facilitate initial public offerings and reverse take-over listings (including through the TSX-Venture Exchange capital pool program), additional offerings (such as standby equity distribution agreements) and dual listings. We also prepare prospectuses and filing statements and organize the clearance of filings with securities regulators and stock exchange listing committees.


We advise life sciences clients in their acquisitions and divestments of businesses or products. Our M&A team manages complex transactions in the life sciences space, whether friendly or contested, and is supported by one of the leading life sciences regulatory teams in Canada.


As cross-border investments and transactions become more complex, we rely on a trusted network of advisors across 47 countries.


We advise clients involved in all aspects of a transaction, including acquirers, targets, boards and their special committees, lenders, financial advisors, investors and key shareholders. We also represent some of the leading investment banks in Canada and Europe operating in the life sciences space. 


Read our publications, browse some of our recent life sciences work we’ve assisted with or contact any of our lawyers to learn more. 



Client Work

  • Edesa Biotech Inc. closes US$3 million private placement,
  • Exzell Pharma Inc. announces its sale to Biolab Pharma Ltd.,
  • Algernon Pharmaceuticals Inc. completes C$1.1 million marketed public offering,
  • GeneTether Therapeutics Inc. completes C$4.5 million initial public offering,
  • Sonic Incytes on its Series A raise of US$7.3 million to accelerate Velacur commercialization,
  • NuChem Sciences acquires OmegaChem,
  • Theratechnologies Inc. establishes a US $50 million at-the-market facility,
  • Edesa Biotech, Inc. closes US$10 million bought deal offering of common shares,
  • Filament Health acquires Psilo Scientific Ltd. ,


    Receive email updates from our team